Renal-limited ANCA-associated vasculitis during erlotinib treatment for lung carcinoma

Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361(10):958–67.

Goto K, Nishio M, Yamamoto N, Chikamori K, Hida T, Maemondo M, Katakami N, Kozuki T, Yoshioka H, Seto T, et al. A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC). Lung Cancer. 2013;82(1):109–14.

Kurita N, Mise N, Fujii A, Ikeda S, Sugimoto T. Crescentic glomerulonephritis in a patient with advanced lung cancer during erlotinib therapy. NDT Plus. 2009;2(6):512–3.

Latcha S, Jaimes EA, Gutgarts V, Seshan S. Case of Proteinuria, Worsening Hypertension, and Glomerular Endotheliosis With Erlotinib and Gefitinib. Kidney Int Rep. 2018;3(6):1477–81.

Gesualdo L, Di Paolo S, Calabró A, Milani S, Maiorano E, Ranieri E, Pannarale G, Schena FP. Expression of epidermal growth factor and its receptor in normal and diseased human kidney: an immunohistochemical and in situ hybridization study. Kidney Int. 1996;49(3):656–65.

Tang J, Liu N, Zhuang S. Role of epidermal growth factor receptor in acute and chronic kidney injury. Kidney Int. 2013;83(5):804–10.

Bollée G, Flamant M, Schordan S, Fligny C, Rumpel E, Milon M, Schordan E, Sabaa N, Vandermeersch S, Galaup A, et al. Epidermal growth factor receptor promotes glomerular injury and renal failure in rapidly progressive crescentic glomerulonephritis. Nat Med. 2011;17(10):1242–50.

Ju W, Nair V, Smith S, Zhu L, Shedden K, Song PXK, Mariani LH, Eichinger FH, Berthier CC, Randolph A et al: Tissue transcriptome-driven identification of epidermal growth factor as a chronic kidney disease biomarker. Sci Transl Med 2015, 7(316):316ra193.

Kamo H, Shinozaki E, Sugase T, Mizunuma N, Taniguchi S, Gotoh T, Chin K, Tanaka T, Koga K, Yamaguchi K. Leukocytoclastic vasculitis with purpura and renal failure induced by the anti-epidermal growth factor receptor antibody panitumumab: a case report. J Med Case Rep. 2019;13(1):13.

Wu L, Li XQ, Goyal T, Eddy S, Kretzler M, Ju WJ, Chen M, Zhao MH. Urinary epidermal growth factor predicts renal prognosis in antineutrophil cytoplasmic antibody-associated vasculitis. Ann Rheum Dis. 2018;77(9):1339–44.

Diez-Porres L, Rios-Blanco JJ, Robles-Marhuenda A, Gutiérrez-Molina M, Gil-Aguado A, Vázquez-Rodríguez JJ. ANCA-associated vasculitis as paraneoplastic syndrome with colon cancer: a case report. Lupus. 2005;14(8):632–4.

Flint J, Morgan MD, Savage CO. Pathogenesis of ANCA-associated vasculitis. Rheum Dis Clin North Am. 2010;36(3):463–77.

Gao Y, Zhao MH. Review article: Drug-induced anti-neutrophil cytoplasmic antibody-associated vasculitis. Nephrology (Carlton). 2009;14(1):33–41.

Malyszko J, Kozlowska K, Kozlowski L. Nephrotoxicity of anticancer treatment. Nephrol Dial Transplant. 2017;32(6):924–36.

Takimoto T, Nakabori T, Osa A, Morita S, Terada H, Oseto S, Iwazawa T, Abe K. Tubular nephrotoxicity induced by docetaxel in non-small-cell lung cancer patients. Int J Clin Oncol. 2012;17(4):395–8.